REMD Biotherapeutics employs several innovative technologies in its drug development efforts, particularly focusing on the GPCR Antibody Platform, SynermAb Bispecific Platform, and the Tumor Activated Interferon (TAI) Platform. The TAI Platform is particularly noteworthy as it aims to enhance the therapeutic potential of interferons, which are known for their anti-tumor properties but often face limitations due to systemic toxicity. By fusing engineered interferons with antibodies that target cancer-specific antigens, the TAI technology allows for targeted delivery to the tumor microenvironment. This approach not only mitigates the adverse effects associated with traditional cytokine therapies but also enhances the therapeutic window, making it a promising avenue for cancer treatment.

The lead candidate from the TAI Platform, REMD-456, is an optimized interferon alpha fused to a PD-L1 antibody, showing potential efficacy against PD-L1+ tumors. Preclinical studies have demonstrated both the safety and effectiveness of this molecule, positioning it for an Investigational New Drug (IND) application in 2025. This strategic focus on targeted therapies underscores REMD Biotherapeutics' commitment to advancing cancer treatment through innovative biotherapeutic platforms that leverage the body's immune response while minimizing systemic side effects.

United States

We, at REMD, are a biopharmaceutical company focused on discovering and developing cutting-edge bio-medicines to treat cancer, diabetes and other diseases. REMD develops world class, high quality, and efficient medicine by uniting top American medical scientists and elite Chinese pharmaceutical assets, leveraging the world's most advanced research and development technologies.

REMD Biotherapeutics

Company Details